iSpecimen (ISPC) to Release Earnings on Thursday

iSpecimen (NASDAQ:ISPCGet Free Report) is expected to announce its results before the market opens on Thursday, March 12th. Analysts expect the company to announce earnings of ($3.80) per share and revenue of $3.4030 million for the quarter.

iSpecimen Stock Performance

Shares of iSpecimen stock opened at $0.26 on Thursday. The stock has a market capitalization of $2.49 million, a P/E ratio of -0.03 and a beta of 1.87. iSpecimen has a 52-week low of $0.23 and a 52-week high of $3.18. The stock’s 50-day simple moving average is $0.32 and its 200 day simple moving average is $0.65.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in iSpecimen stock. Virtu Financial LLC bought a new stake in shares of iSpecimen Inc. (NASDAQ:ISPCFree Report) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 63,257 shares of the company’s stock, valued at approximately $82,000. Virtu Financial LLC owned approximately 0.65% of iSpecimen as of its most recent SEC filing. Institutional investors own 13.62% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of iSpecimen in a research report on Thursday, January 22nd. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company has a consensus rating of “Sell”.

Read Our Latest Research Report on ISPC

iSpecimen Company Profile

(Get Free Report)

iSpecimen, Inc (NASDAQ:ISPC) operates an online life sciences marketplace designed to connect researchers with human biological specimens and associated clinical data. The company’s platform streamlines the sourcing of biospecimens—such as plasma, serum, fresh and frozen tissue, saliva, urine and peripheral blood mononuclear cells (PBMCs)—by matching demand from pharmaceutical, biotechnology, diagnostic and academic organizations with supply from a wide network of clinical sites and biobanks.

Through its on-demand procurement model, iSpecimen provides customized specimen collection and fulfillment services that help accelerate research timelines and improve data quality.

Read More

Earnings History for iSpecimen (NASDAQ:ISPC)

Receive News & Ratings for iSpecimen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iSpecimen and related companies with MarketBeat.com's FREE daily email newsletter.